Brainstorm Cell Therapeutics Inc GHDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GHDN is a good fit for your portfolio.
News
-
Brainstorm Cell Therapeutics shares fall more than 50% after FDA advisors vote down ALS treatment
-
BrainStorm Shares Plummet Premarket After Negative FDA Panel Vote
-
FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics
-
FDA Panel Rejects Brainstorm Cell Therapeutics ALS Treatment
-
BrainStorm Shares Halted Before FDA Meeting for NurOwn BLA
Trading Information
- Previous Close Price
- $0.40
- Day Range
- $0.44–0.46
- 52-Week Range
- $0.11–14.90
- Bid/Ask
- $0.42 / $0.46
- Market Cap
- $31.89 Mil
- Volume/Avg
- 2,500 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.brainstorm-cell.com
Comparables
Valuation
Metric
|
GHDN
|
MORF
|
RYTM
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.00 | 42.34 |
Price/Sales | — | — | 27.23 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
GHDN
|
MORF
|
RYTM
|
---|---|---|---|
Quick Ratio | 0.12 | 37.20 | 3.99 |
Current Ratio | 0.18 | 38.17 | 4.35 |
Interest Coverage | −28.53 | — | −17.19 |
Quick Ratio
GHDN
MORF
RYTM
Profitability
Metric
|
GHDN
|
MORF
|
RYTM
|
---|---|---|---|
Return on Assets (Normalized) | −258.37% | −18.85% | −77.30% |
Return on Equity (Normalized) | — | −19.43% | −148.97% |
Return on Invested Capital (Normalized) | — | −23.26% | −146.66% |
Return on Assets
GHDN
MORF
RYTM
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
VRTX
| Hzhjtgrc | Chvzpdt | $124.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Jhqfwltzw | Qsmtwb | $114.2 Bil | |||
Moderna Inc
MRNA
| Rxctrnvq | Mmwff | $53.7 Bil | |||
argenx SE ADR
ARGX
| Fnpgqjtzl | Nphmt | $23.0 Bil | |||
BioNTech SE ADR
BNTX
| Wndhpmlqq | Fmfrx | $22.2 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Hgxkjszs | Xgjpwv | $20.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pcfdfkkd | Gxgxvr | $15.9 Bil | |||
United Therapeutics Corp
UTHR
| Lwzwdty | Jtpz | $12.8 Bil | |||
Incyte Corp
INCY
| Djdykvm | Knygv | $12.2 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Bxdhwxms | Fxkytj | $12.2 Bil |